European Medicine Agency (EMA) announces the discontinuation of Daclizumab (Zinbryta) in Multiple Sclerosis patients

Starting 2017, Daclizumab (Zinbryta) was convenient and more advanced in the treatment of multiple sclerosis which has broken out with other medical treatment.

Discontinuation is in short term due to investigation of  the death of a patient with fulminant hepatic impairment in one observational study and after four other cases of severe liver damage were reported.

Note : Daclizumab (Zinbryta) was not intended for patient with liver disease

http://lequotidiendupharmacien.fr